ATE405324T1 - Formulierungen mit kontrollierter freisetzung, die tryptophan und/oder 5-hydroxytryptophan enthalten - Google Patents

Formulierungen mit kontrollierter freisetzung, die tryptophan und/oder 5-hydroxytryptophan enthalten

Info

Publication number
ATE405324T1
ATE405324T1 AT05107894T AT05107894T ATE405324T1 AT E405324 T1 ATE405324 T1 AT E405324T1 AT 05107894 T AT05107894 T AT 05107894T AT 05107894 T AT05107894 T AT 05107894T AT E405324 T1 ATE405324 T1 AT E405324T1
Authority
AT
Austria
Prior art keywords
hydroxytryptophan
release
controlled
containing tryptophan
formulations containing
Prior art date
Application number
AT05107894T
Other languages
English (en)
Inventor
Bojidar Mihaylov Stankov
Original Assignee
Ambros Pharma S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambros Pharma S R L filed Critical Ambros Pharma S R L
Application granted granted Critical
Publication of ATE405324T1 publication Critical patent/ATE405324T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AT05107894T 2004-09-01 2005-08-29 Formulierungen mit kontrollierter freisetzung, die tryptophan und/oder 5-hydroxytryptophan enthalten ATE405324T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001689A ITMI20041689A1 (it) 2004-09-01 2004-09-01 Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano

Publications (1)

Publication Number Publication Date
ATE405324T1 true ATE405324T1 (de) 2008-09-15

Family

ID=35385157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05107894T ATE405324T1 (de) 2004-09-01 2005-08-29 Formulierungen mit kontrollierter freisetzung, die tryptophan und/oder 5-hydroxytryptophan enthalten

Country Status (5)

Country Link
US (1) US7670619B2 (de)
EP (1) EP1637185B1 (de)
AT (1) ATE405324T1 (de)
DE (1) DE602005009090D1 (de)
IT (1) ITMI20041689A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
IT1397888B1 (it) * 2009-12-23 2013-02-04 Ambros Pharma S R L Procedimento per la preparazione di compresse a due strati comprendenti 5-idrossitriptofano e triptofano.
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP2014503592A (ja) 2011-01-26 2014-02-13 ニコ ワールドワイド，インコーポレイテッド 片頭痛の療法
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012109216A1 (en) 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
SI2988824T1 (sl) 2013-04-23 2019-02-28 Zx Pharma, Llc Večenotni obloženi gastrorezistentni pripravek s proteinsko podoblogo
IL270179B2 (en) 2017-04-25 2024-07-01 Temple Otorongo Llc A pharmaceutical preparation containing tryptophan and a phyllokinin derivative for the treatment of psychiatric and psychological disorders
US11464756B1 (en) * 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
EP3810111A4 (de) 2018-06-19 2022-03-23 National University of Singapore Formulierungen von 5-hydroxytryptophan (5-htp) zur besseren bioverfügbarkeit für verschiedene indikationen
BE1028307B9 (fr) 2020-05-14 2022-03-14 Aminuki Aliments complémentaires pour animaux comprenant GABA, 5-HTP et cofacteurs ciblés
KR20240039030A (ko) 2021-07-30 2024-03-26 에벡시아 테라퓨틱스 아이엔씨. 5-하이드록시트립토판 위체류성 투여 형태
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1378296A (en) 1971-11-24 1974-12-27 Beecham Group Ltd Pharmaceutical composition
CN1211078C (zh) 1998-05-15 2005-07-20 中外制药株式会社 控释制剂
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands

Also Published As

Publication number Publication date
DE602005009090D1 (de) 2008-10-02
EP1637185B1 (de) 2008-08-20
US20060045913A1 (en) 2006-03-02
EP1637185A1 (de) 2006-03-22
US7670619B2 (en) 2010-03-02
ITMI20041689A1 (it) 2004-12-02

Similar Documents

Publication Publication Date Title
ATE405324T1 (de) Formulierungen mit kontrollierter freisetzung, die tryptophan und/oder 5-hydroxytryptophan enthalten
AU2020286208B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
CN107868071B (zh) 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法
JP7132907B2 (ja) ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
BR112013025420B1 (pt) Medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento
TW200819144A (en) Composition with increased photo-stability
JP5743177B2 (ja) 新規剤形
JP4970244B2 (ja) エスゾピクロンを用いる治療方法
CN105492010B (zh) 用于治疗相移睡眠障碍的V1a拮抗剂
UA71613C2 (uk) Спосіб одержання фармацевтичного препарату перорального введення з уповільненим вивільненням толперизону (варіанти)
WO2012173581A4 (en) Thiocolchicoside, etodolac and famotidine combinations
OA11276A (en) Novel composition comprising an ssri and a beta-b locker.
JP2023525840A (ja) メチルフォレートを含む組成物
RU2007142557A (ru) Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
JP2008201712A (ja) フィルムコーティング製剤
EA025692B1 (ru) Применение модафинила для лечения кокаиновой зависимости
KR20080098964A (ko) 클로피도그렐 황산수소염을 함유하는 약학적 조성물 및 그제조방법
CA3058507A1 (en) Multivitamin composition for improving verbal fluency, decreasing performance anxiety symptoms and method for preparing same
JP4096127B2 (ja) 酒さ治療剤
BG330Y1 (bg) Твърда дозирана лекарствена форма на комбиниранантихипоксичен препарат
CN104434881A (zh) 一种盐酸他喷他多缓释微丸及其制备方法
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos
EA021368B1 (ru) Препарат кардиопротекторного действия

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1637185

Country of ref document: EP